Testing the safety of an RSV antibody in infants
Part of Immune system & allergy, Infections clinical trials.
This study checks if it is safe to delay the RSV preventive antibody shot by up to two weeks in infants who are getting their routine vaccines. Your baby will get the antibody at a second visit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be between 6 weeks and 30 weeks old
- Your baby is already scheduled to receive an RSV antibody shot
- Your baby is getting at least one routine childhood vaccine
- You must be able to read and understand English or Spanish
- You must be able to bring your baby to two visits and be reachable by phone
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how your body's immune system responds to a new respiratory syncytial virus (RSV) vaccine. RSV is a common virus that causes respiratory infections, especially in older adults. The vaccine may help protect you from RSV disease.
This study tests whether giving a special antibody medicine (called RSV-SMA) to babies aged 6–9 months can help prevent respiratory syncytial virus (RSV), a common virus that causes serious breathing problems in young children. Your baby would receive the medicine and be followed to see if it helps protect them.
This trial tests two ways to protect babies from RSV: a vaccine given to pregnant women, and an antibody shot given to newborns. Both are already approved—this study checks if using them together works better than either alone.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This study looks at how well RSV vaccines or antibody shots protect babies from severe respiratory infections. If your baby is under 1 year old, lives in Connecticut, and gets sick with a respiratory infection, they may be able to join.
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
Hear when a new Fever trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.